In a reciprocal manner, LDN-193189 could be more effective if given prior to osteochondroma initiation or even chronically and if it were to be tested in less aggressive HME mouse models, such as single Ext1+/- or double heterozygous Ext1+/-;Ext2+/- mice [24]. The gene discussed is EXT2; the disease is Osteochondroma.